MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$11,443K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Share-based compensation expense
Accounts payable and accrued exp...
Prepaid expenses
Depreciation expense
Negative Cash Flow Breakdown
Net income (loss) before noncont...
Other current assets
Change in fair value of warrants...
Change in fair value of warrants...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss) before noncontrolling interest
-13,054
24,134
-7,138
-10,345
Depreciation expense
1
1
2
2
Loss on disposal of property and equipment
-
-
-6
-
Loss from g42 promissory note early redemption
-
-
0
-
Non-cash interest income
-
-
0
-
Share-based compensation expense
1,727
1,388
1,025
1,007
Realized gain on sale of investment in reneo pharmaceuticals, inc
-
-
0
-
Impairment of investments in anteris bio, inc
-
-
0
-
Change in fair value of warrants, related party-Related Party
-35
-24
47
6
Change in fair value of warrants, related party-Nonrelated Party
-29
-9
70
34
Prepaid expenses
-105
-222
-97
481
Other current assets
329
-17
106
19
Other assets
0
0
-24
-34
Accounts payable and accrued expenses
171
264
-3,246
4,587
Contract liabilities
0
-16,839
0
-
Other liabilities
0
0
-32
-47
Net cash used in operating activities
-11,443
9,154
-9,251
-5,222
Proceed from sale of investments in reneo pharmaceuticals, inc
-
-
0
-
Net cash provided by (used in) investing activities
-
-
0
-
Proceeds from sale of class a common stock, pre-funded and common warrants, net of offering costs
-
-
0
77,476
Proceeds from sale of class a common stock and pre-funded warrants, net of offering costs
-
-
0
0
Proceeds from issuance of class a common stock, net of offering costs
-
-
0
0
Proceeds from sale of class a common stock to collaboration partner, net of offering costs
-
-
0
-
Proceeds from the exercise of stock options
0
-
7
0
Taxes paid related to net share settlement of equity awards
0
-
0
0
Proceeds from debt issuance
-
-
0
392
Repayment of notes payable
-
-
328
64
Net cash used in financing activities
0
-
-321
77,804
Net decrease in cash and cash equivalents
-11,443
9,154
-9,572
72,582
Total cash and cash equivalents, beginning of period
98,086
88,932
98,504
36,746
Total cash and cash equivalents, end of period
86,643
98,086
88,932
98,504
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net decrease in cash
and cash...
-$11,443K
(-5.72%↓ Y/Y)
Share-based compensation
expense
$1,727K
(-0.92%↓ Y/Y)
Accounts payable and
accrued expenses
$171K
(-9.52%↓ Y/Y)
Prepaid expenses
-$105K
(87.39%↑ Y/Y)
Depreciation expense
$1K
(-91.67%↓ Y/Y)
Net cash used in
operating activities
-$11,443K
(-6.13%↓ Y/Y)
Canceled cashflow
$2,004K
Net income (loss)
before noncontrolling...
-$13,054K
(3.99%↑ Y/Y)
Other current assets
$329K
(501.22%↑ Y/Y)
Change in fair value of
warrants, related...
-$35K
(-34.62%↓ Y/Y)
Change in fair value of
warrants, related...
-$29K
(-680.00%↓ Y/Y)
Buy us a coffee
vTv Therapeutics Inc. (VTVT)
vTv Therapeutics Inc. (VTVT)